HONOLULU -- Motavizumab, a humanized monoclonal antibody to respiratory syncytial virus (RSV) reduced hospital admissions among American-Indian infants by 83% compared with placebo, in a phase III study, researchers reported here.
PAS: Motavizumab Cuts RSV Infection and Hospitalization RatesCourtesy MedPage Today Infectious Disease Mon, 05/05/2008 - 11:24
HONOLULU -- Motavizumab, a humanized monoclonal antibody to respiratory syncytial virus (RSV) reduced hospital admissions among American-Indian infants by 83% compared with placebo, in a phase III study, researchers reported here. Tags:
More related itemsBritish Medical Journal: Brain drain starts at age...
Heart disease study highlights Scottish ethnic groups...
New method boosts blood-clotting for hemophiliacs
Burt's Bees - Baby Bee Buttermilk Lotion, 7 fl oz...
ghd MK4 Professional Advanced Ceramic Heat-Styler, 1"
|
Popular by tags WeekMonth |
Post new comment